Efficacy of (E)-5-(2-bromovinyl)-2'-deoxyuridine in the treatment of experimental herpes simplex virus encephalitis in mice.
Systemic treatment of mice with (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) showed a significant therapeutic efficacy against herpes simplex type 1 virus (HSV-1) encephalitis. With treatment initiated 12 h after viral inoculation and continued for 10 consecutive days, BVDU administered intraperitoneally in daily doses of 100-500 mg/kg increased the 21-day survival rates from 30 to 100% and reduced brain virus titers by 3-4 log10 on day 6 post-infection. Furthermore, at doses of 300-500 mg/kg per day BVDU prevented the establishment of latent virus infection in the trigeminal ganglia following intracerebral HSV-1 inoculation.
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use; D001921:Brain / Q000382:microbiology; D001973:Bromodeoxyuridine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004660:Encephalitis / Q000188:drug therapy* / Q000382:microbiology; D005724:Ganglia / Q000382:microbiology; D006561:Herpes Simplex / Q000188:drug therapy* / Q000382:microbiology; D008297:Male; D051379:Mice; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; C020235:brivudine; D001973:Bromodeoxyuridine